On August 29, 2024 Abcuro, Inc., a clinical stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, reported that Alex Martin, Chief Executive Officer, will present at the following investor conferences (Press release, Abcuro, AUG 29, 2024, View Source [SID1234646192]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 22nd Annual Global Healthcare Conference: Presentation on September 5, 2024, at 2:35 pm E.T.
Stifel Virtual Immunology and Inflammation Summit: Presentation on September 18, 2024, at 2:00 pm E.T.